Online inquiry

IVTScrip™ mRNA-Anti-MST1R, IMC RON-8(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) (CAT#: GTTS-WQ9021MR)

This product GTTS-WQ9021MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets MST1R gene. The antibody can be applied in Solid tumors research.

Specifications
Product type	mRNA
Modified bases	5-Methoxy-UTP
5' Cap	Cap 0
Species	Homo sapiens
RefSeq	NM_001244937.3
Applications	Gene therapy research
Format	Powder
Quantity	100 µg
Purification	oligo-dT affinity purification

Target Gene
Gene ID	4486
UniProt ID	Q04912

Download
Download resources about mRNA therapeutics development to boost your research.

CUSTOMER REVIEWS and Q&As
There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MST1R, IMC RON-8(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ9021MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT	Product Name	Product Type	CDs
GTTS-WQ5580MR	IVTScrip™ mRNA-Anti-IL13, CDP7766(Cap 0, Pseudo-UTP, 30 nt-poly(A))	mRNA	CDP7766
GTTS-WQ5752MR	IVTScrip™ mRNA-Anti-EGFR, CetuxiMab-GEX(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))	mRNA	CetuxiMab-GEX
GTTS-WQ13375MR	IVTScrip™ mRNA-Anti-LRRC15, PR-1498487(Cap 0, 5-Methyl-CTP, 120 nt-poly(A))	mRNA	PR-1498487
GTTS-WQ7125MR	IVTScrip™ mRNA-Anti-LHCGR, FE 999302(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A))	mRNA	FE 999302
GTTS-WQ5873MR	IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, CIFN(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))	mRNA	CIFN
GTTS-WQ10188MR	IVTScrip™ mRNA-Anti-ITGA4&ITGB7, LDP-02(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))	mRNA	LDP-02
GTTS-WQ10332MR	IVTScrip™ mRNA-Anti-IL17A&TNFSF13B, LY 3090106(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))	mRNA	LY 3090106
GTTS-WQ8411MR	IVTScrip™ mRNA-Anti-HSP90, HSP90mab(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))	mRNA	HSP90mab

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST